Article
The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.
Surgical pathology clinics - 1 Sept 2022
Mohindroo Chirayu, De Jesus-Acosta Ana, Yurgelun Matthew B, Maitra Anirban, Mork Maureen, McAllister Florencia
Abstract excerpt
Identification of deleterious germline mutations in pancreatic ductal adenocarcinoma (PDAC) patients can have therapeutic implications for the patients and result in cascade testing and prevention in their relatives. Universal testing for germline mutations is now considered standard of care in patients with PDAC, regardless of family history, personal history, or age. Here, we highlight the commonly identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.